Physician profile
David P Ramirez
NPI 1487684890
$3,117.09
in general payments reported to CMS, 2019-2025
27 companies · $320 in 2025
The $320 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $466 · 2021: $752 · 2022: $282 · 2023: $552 · 2024: $415 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,287.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $756.75 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $339.69 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $286.01 | 2021-2024 | |
| Novo Nordisk INC | $169.87 | 2019-2024 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $168.83 | 2019-2021 | |
| Amgen INC. | $153.08 | 2019-2024 | Otezla, Repatha |
| Pfizer INC. | $143.16 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $138.71 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.58 | 2019-2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.71 | 2023-2024 | Xifaxan |
| Eisai INC. | $102.20 | 2020-2021 | |
| Tris Pharma INC | $84.29 | 2023-2025 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $80.80 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Allergan, INC. | $78.78 | 2020 | |
| Exact Sciences Corporation | $77.13 | 2023-2024 | Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $65.92 | 2024-2025 | Voquezna |
| Abbott Laboratories | $50.07 | 2022-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $43.31 | 2020-2021 | |
| Genentech USA, INC. | $39.10 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.61 | 2023 | Hyqvia |
| Antares Pharma, INC. | $18.04 | 2025 | Xyosted |
| Astellas Pharma US INC | $16.97 | 2019 | |
| Neos Therapeutics, LP | $14.68 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.81 | 2021 | |
| Nabriva Therapeutics, Plc | $12.31 | 2020 | |
| Esperion Therapeutics, INC. | $11.70 | 2020 | |
| Endogastric Solutions, INC | $8.98 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.